AbbVie (ABBV) Wins Two FDA Breakthrough Tags, Is The Stock Fully Priced?
AbbVie (ABBV) Wins Two FDA Breakthrough Tags, Is The Stock Fully Priced? Simply Wall Street
Covered in this story
Analyst targets on AbbVie
- UBS: $276 → $275 by Oct 2027 · Neutral via GuruFocus
- Bank of America: $262 → $289 by Sep 2027 · Buy via AOL.com
- Wolfe Research: $263 → $300 by Sep 2027 · Outperform via Yahoo Finance
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 46 stories mentioning AbbVie, the earliest published 29 Apr 2026.
Summary aggregated from Simply Wall Street's public RSS feed. The full reporting belongs to Simply Wall Street — please read it on their site.